Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 247
2.
Clin Pharmacol Ther ; 90(2): 263-70, 2011 Aug.
Article En | MEDLINE | ID: mdl-21716273

Microdosing studies are effective in enabling the early identification of the pharmacokinetic properties of compounds administered to humans. However, the nonlinearity of the pharmacokinetics between microdose and therapeutic dose, attributable to the saturation of metabolic enzymes and transporters, is a major concern. Verapamil and quinidine are good substrates of both the multidrug resistance 1 transporter (MDR1) and the cytochrome P450 (CYP) 3A4 enzyme (CYP3A4). We investigated their dose-dependent pharmacokinetics in healthy subjects. Four different doses of verapamil or quinidine were administered orally to each subject, and the plasma concentrations of the parent drugs and their major metabolites were measured. The dose-normalized area under the plasma concentration-time curve (AUC) values of quinidine and verapamil increased in a dose-dependent manner and were 2.6- and 2.3-fold higher, respectively, at the therapeutic dose than at microdose. These results suggest that the nonlinear pharmacokinetics of these drugs is caused mainly by the saturation of MDR1 and/or CYP3A4 in the small intestine.


ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Cytochrome P-450 CYP3A/metabolism , Intestine, Small/metabolism , Quinidine/pharmacokinetics , Verapamil/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B , Administration, Oral , Adult , Area Under Curve , Dose-Response Relationship, Drug , Humans , Male , Quinidine/administration & dosage , Verapamil/administration & dosage , Young Adult
3.
Bone Marrow Transplant ; 45(1): 111-6, 2010 Jan.
Article En | MEDLINE | ID: mdl-19448678

We report the safety and feasibility of autologous CD133+ cell implantation into the lower extremity muscles of patients with critical limb ischemia, whose only other option was limb amputation. Nine patients participated in the study: seven patients suffering from arteriosclerosis obliterans, one with thromboangiitis obliterans (Buerger's disease) and one with thromboembolic disorder. Autologous PBSC were collected after the administration of G-CSF (10 mcg/kg/day). CD133+ cells were selected using the CLINIMACS cell separation device and were injected i.m. without earlier cryopreservation using a 22-gauge needle into multiple sites 3 cm apart in the gastrocnemius/soleus muscle, or depending on clinical circumstances, in the foot or quadriceps muscle, or both, of the involved leg. There were no complications from either leukapheresis or injection. Stem cell injection prevented leg amputation in seven of the nine patients. In this small cohort of patients with end-stage critical limb ischemia, quality of life (Short Form-36) physical component score improved significantly at 3 (P=0.02) and 6 (P=0.01) months, but not at 1 year (P=0.08). There was a trend towards the improvement in pain-free treadmill walking time (P=0.13) and exercise capacity (P=0.16) at 1 year. Lower extremity limb salvage was achieved for seven of the nine treated patients.


Ischemia/surgery , Leg/blood supply , Leukocyte Transfusion/methods , Limb Salvage/methods , AC133 Antigen , Adult , Aged , Aged, 80 and over , Antigens, CD/metabolism , Arteriosclerosis Obliterans/surgery , Female , Glycoproteins/metabolism , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Mobilization/methods , Humans , Leg/surgery , Leukapheresis/methods , Leukocytes/immunology , Male , Middle Aged , Peptides/metabolism , Thromboangiitis Obliterans/surgery , Transplantation, Autologous
4.
Clin Nephrol ; 72(1): 46-54, 2009 Jul.
Article En | MEDLINE | ID: mdl-19640387

BACKGROUND: Proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) associated with membranoproliferative features is an extremely rare entity. Information on clinicopathological features and prognosis in this entity is limited. METHODS: We reviewed 5,443 renal biopsies processed at our department, and identified 4 patients with PGNMID associated with membranoproliferative features. We evaluated clinicopathological features and outcomes in these patients, and characterized paraprotein deposits by immunofluorescence studies. RESULTS: Three out of 4 patients had nephrotic syndrome with renal insufficiency at presentation. Cryoglobulin or monoclonal protein in serum and urine was not detected. Renal biopsy showed membranoproliferative features with or without nodular formation. Tubulointerstitial and vascular alterations were mild in three patients. All patients had glomerular IgG-kappa deposits. Heavy chain subclass analysis performed in 3 patients showed IgG3 deposits. Immunofluorescence studies using antibodies specific for gamma-heavy chain C(H)1, C(H)2, and C(H)3 domains and gamma3 hinge did not show any apparent deletion. Confocal microscopy revealed glomerular colocalization of light and heavy chains. On electron microscopy, granular deposits were predominantly mesangial and subendothelial. All patients were treated with steroids and cytotoxic agents, but no effect on proteinuria was observed. The renal outcome was progressive in all patients. Early death was observed in two elder patients. No patient had overt myeloma or lymphoma at presentation or over the course of follow-up (mean 43 months). CONCLUSIONS: Our study suggests a predominance of IgG3-kappa glomerular deposits of nondeleted whole immunoglobulin molecules in PGNMID associated with membranoproliferative features. The clinical outcome in patients with this entity appears to be poor.


Glomerulonephritis, Membranoproliferative/immunology , Immunoglobulin G/immunology , Adult , Aged , Aged, 80 and over , Biopsy , Female , Fluorescent Antibody Technique , Glomerulonephritis, Membranoproliferative/epidemiology , Glomerulonephritis, Membranoproliferative/pathology , Humans , Incidence , Japan/epidemiology , Male , Microscopy, Confocal , Microscopy, Electron , Middle Aged
5.
Neuromuscul Disord ; 2009 Mar 24.
Article En | MEDLINE | ID: mdl-19324549

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

6.
Ann Rheum Dis ; 67(7): 991-7, 2008 Jul.
Article En | MEDLINE | ID: mdl-17947303

OBJECTIVE: For patients with systemic vasculitis (SV) refractory to conventional therapy, new treatment strategies aimed at aggressive induction of remission and relapse prevention are being sought. We herein report our single-centre experience in treating four patients with refractory SV employing non-myeloablative autologous haematopoietic stem cell transplantation (HSCT). METHODS: Four patients with refractory SV (two with neurovascular Behcet disease, one with neurovascular Sjögren syndrome, and one with Wegener granulomatosis) were involved in an Institutional Review Board (IRB) and US Food and Drug Administration (FDA) approved phase I clinical trial of high dose chemotherapy and autologous HSCT. Peripheral blood stem cells were mobilised with cyclophosphamide (Cy) and granulocyte-colony stimulating factor (G-CSF). Conditioning regimen consisted of Cy 200 mg/kg and rabbit anti-thymocyte globulin 5.5 mg/kg intravenously (iv). RESULTS: All four patients tolerated HSCT well without transplant related mortality or any significant toxicity. At median follow-up of 28 (range 22-36) months all patients were alive. Three patients (one with Behcet disease, one with Sjögren syndrome, and one with Wegener granulomatosis) entered a sustained remission at 6, 6 and 24 months, respectively, after transplant. They had significant decrease in disease activity and disease or treatment related damage, as measured by the Birmingham Vasculitis Activity Score and Vasculitis Damage Index, respectively. All three patients who achieved remission discontinued immunosuppressive therapy at the time of transplant and have not required treatment since. One patient with Behcet disease and positive for human leukocyte antigen (HLA)-B51 has not improved after HSCT. CONCLUSION: We suggest non-myeloablative autologous HSCT is an alternative therapy for select patients with SV refractory to conventional immunosuppressive therapies.


Hematopoietic Stem Cell Transplantation/methods , Vasculitis/therapy , Adult , Biomarkers/blood , Blood Component Transfusion/methods , Female , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Immunosuppressive Agents/therapeutic use , Magnetic Resonance Imaging , Remission Induction , Severity of Illness Index , Transplantation Conditioning/methods , Treatment Outcome , Vasculitis/drug therapy
8.
Bone Marrow Transplant ; 40(6): 549-55, 2007 Sep.
Article En | MEDLINE | ID: mdl-17646844

Autologous hematopoietic stem cell transplantation (HSCT) utilizing a myeloablative regimen containing total body irradiation has been performed in patients with systemic sclerosis (SSc), but with substantial toxicity. We, therefore, conducted a phase I non-myeloablative autologous HSCT study in 10 patients with SSc and poor prognostic features. PBSC were mobilized with CY and G-CSF. The PBSC graft was cryopreserved without manipulation and re-infused after the patient was treated with a non-myeloablative conditioning regimen of 200 mg/kg CY and 7.5 mg/kg rabbit antithymocyte globulin. There was a statistically significant improvement of modified Rodnan skin score whereas cardiac (ejection fraction, pulmonary arterial pressure), pulmonary function (DLCO) and renal function (creatinine) remained stable without significant change. One patient with advanced disease died 2 years after the transplant from progressive disease. After median follow-up of 25.5 months, the overall and progression-free survival rates are 90 and 70% respectively. Autologous HSCT utilizing a non-myeloablative conditioning regimen appears to result in improved skin flexibility similar to a myeloablative TBI containing regimen, but without the toxicity and risks associated with TBI.


Hematopoietic Stem Cell Transplantation , Scleroderma, Systemic/therapy , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods , Adult , Blood Sedimentation , Child , Erythrocyte Transfusion , Female , Follow-Up Studies , Humans , Kidney Function Tests , Male , Middle Aged , Platelet Transfusion , Prognosis , Pulmonary Wedge Pressure , Respiratory Function Tests , Skin , Stroke Volume , Survival Rate , Transplantation, Autologous , Treatment Outcome
9.
Bone Marrow Transplant ; 40(1): 47-53, 2007 Jul.
Article En | MEDLINE | ID: mdl-17483845

Patients with cardiac dysfunction may be at increased risk of cardiac toxicity when undergoing hematopoietic stem cell transplantation (HSCT), which may preclude them from receiving this therapy. Cardiac dysfunction is, however, common in systemic lupus erythematosus (SLE) patients. While autologous HSCT (auto-HSCT) has been performed increasingly for SLE, its impact on cardiac function has not previously been evaluated. We, therefore, performed a retrospective analysis of SLE patients who had undergone auto-HSCT in our center to determine the prevalence of significant cardiac involvement, and the impact of transplantation on this. The records of 55 patients were reviewed, of which 13 were found to have abnormal cardiac findings on pre-transplant two-dimensional echocardiography or multi-gated acquisition scan: impaired left ventricular ejection fraction (LVEF) (n = 6), pulmonary hypertension (n = 5), mitral valve dysfunction (n = 3) and large pericardial effusion (n = 1). At a median follow-up of 24 months (8-105 months), there were no transplant-related or cardiac deaths. With transplant-induced disease remission, all patients with impaired LVEF remained stable or improved; while three with symptomatic mitral valve disease similarly improved. Elevated pulmonary pressures paralleled activity of underlying lupus. These data suggest that auto-HSCT is feasible in selected patients with lupus-related cardiac dysfunction, and with control of disease activity, may improve.


Heart Diseases/complications , Heart Valve Diseases/therapy , Hematopoietic Stem Cell Transplantation , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/therapy , Ventricular Dysfunction/therapy , Cyclophosphamide/therapeutic use , Filgrastim , Granulocyte Colony-Stimulating Factor/therapeutic use , Heart Diseases/diagnostic imaging , Heart Diseases/therapy , Heart Valve Diseases/diagnostic imaging , Hematopoietic Stem Cell Mobilization/methods , Humans , Lupus Erythematosus, Systemic/mortality , Radionuclide Imaging , Recombinant Proteins , Retrospective Studies , Survival Rate , Transplantation, Autologous , Ventricular Dysfunction/diagnostic imaging
11.
Bone Marrow Transplant ; 39(6): 317-29, 2007 Mar.
Article En | MEDLINE | ID: mdl-17277794

Peripheral blood stem cells (PBSC) were mobilized in 130 patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation using cyclophosphamide 2 g/m(2) and either granulocyte colony-stimulating factor (G-CSF) 5 mcg/kg/day (for systemic lupus erythematosus (SLE) and secondary progressive multiple sclerosis, SPMS) or G-CSF 10 mcg/kg/day (for relapsing remitting multiple sclerosis (RRMS), Crohn's disease (CD), systemic sclerosis (SSc), and other immune-mediated disorders). Mobilization-related mortality was 0.8% (one of 130) secondary to infection. Circulating peripheral blood (PB) CD34(+) cells/microl differed significantly by disease. Collected CD34(+) cells/kg/apheresis and overall collection efficiency was significantly better using Spectra apheresis device compared to the Fenwall CS3000 instrument. Patients with SLE and RRMS achieved the lowest and the highest CD34(+) cell yields, respectively. Ex vivo CD34(+) cell selection employing Isolex 300iv2.5 apparatus was significantly more efficient compared to CEPRATE CS device. Circulating PB CD34(+) cells/microl correlated positively with initial CD34(+) cells/kg/apheresis and enriched product CD34(+) cells/kg. Mean WBC and platelet engraftment (ANC>0.5 x 10(9)/l and platelet count >20 x 10(9)/l) occurred on days 9 and 11, respectively. Infused CD34(+) cell/kg dose showed significant direct correlation with faster white blood cell (WBC) and platelet engraftment. When adjusted for CD34(+) cell/kg dose, patients treated with a myeloablative regimen had significantly slower WBC and platelet recovery compared to non-myeloablative regimens.


Antigens, CD34/isolation & purification , Autoimmune Diseases/blood , Hematopoietic Stem Cell Mobilization , Leukapheresis/instrumentation , Peripheral Blood Stem Cell Transplantation , Adolescent , Adult , Autoimmune Diseases/therapy , Female , Humans , Leukapheresis/methods , Male , Middle Aged , Transplantation, Autologous
12.
Bone Marrow Transplant ; 38(6): 453-60, 2006 Sep.
Article En | MEDLINE | ID: mdl-16951693

We have investigated the influence of different hematopoietic growth factors, including granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF), Flt-3 ligand (Flt-3L) and thrombopoietin (TPO), on the course of relapsing experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. Disease course and central nervous system histology were evaluated in all groups. When given after immunization but before either disease onset or during remission, Flt-3L, SCF and G-CSF exacerbated disease severity whereas TPO had no effect compared to non-cytokine-treated controls. When compared to controls, TPO did not exacerbate disease. We conclude that autoimmune disease severity may be affected by hematopoietic growth factors currently being employed in hematopoietic stem cell transplantation of patients with autoimmune disease. The mechanism of their effects remains unknown: it may be related to both T helper (Th) 1/Th2 skewing and/or homing of inflammatory cells to the disease-affected organ.


Encephalomyelitis, Autoimmune, Experimental/blood , Hematopoietic Cell Growth Factors/adverse effects , Hematopoietic Cell Growth Factors/pharmacology , Multiple Sclerosis/blood , Animals , Cell Movement/drug effects , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/pathology , Encephalomyelitis, Autoimmune, Experimental/therapy , Female , Hematopoietic Cell Growth Factors/blood , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cells/metabolism , Hematopoietic Stem Cells/pathology , Mice , Multiple Sclerosis/pathology , Multiple Sclerosis/therapy , Th1 Cells/metabolism , Th1 Cells/pathology , Th2 Cells/metabolism , Th2 Cells/pathology
13.
Br J Dermatol ; 154(1): 90-8, 2006 Jan.
Article En | MEDLINE | ID: mdl-16403100

BACKGROUND: Mucous membrane pemphigoid (MMP), a chronic autoimmune subepithelial blistering disease, is associated with circulating IgG and/or IgA autoantibodies against several basement membrane zone antigens. The heterogeneity of clinical presentation and diversity of target autoantigens have contributed to difficulties in characterizing this condition immunologically. OBJECTIVES: To analyse serum autoantibody profile and HLA class II alleles in MMP patients and to correlate this with the clinical presentation of disease. METHODS: Well-defined subgroups consisting of 124 patients with MMP were examined for IgG and IgA reactivity with immunoblotting using human epidermal, dermal and placental amnion proteins. The results were further analysed on the basis of detailed clinical (sites of involvement and disease severity) and immunopathological criteria (immunofluorescence study and HLA class II alleles). RESULTS: Immunoblot assay revealed that the majority of MMP patients had IgG (93 of 124, 75%) and/or IgA autoantibodies (63 of 124, 51%) to BP180 (including its soluble ectodomains, 120-kDa LAD-1 and 97-kDa LABD97 antigens). Other antigens targeted predominantly by IgG autoantibodies included: BP230 in 34 (27%), beta4 integrin in 26 (21%), and laminin 5 in three (2%). All the BP230+ sera and 23 (88%) beta4 integrin+ sera also reacted with at least one of the BP180 antigens. Over 85% of patients with reactivity to beta4 integrin had ocular involvement. In most cases of MMP, more severe clinical features were associated with antibody reactivity to multiple basement membrane zone antigens, as well as reactivity to multiple BP180 component antigens. Dual BP180/LAD-1 reactivity with IgG and IgA was associated with a more severe phenotype. In addition, the subset-dependent autoantibody reactivity correlated well with specific HLA class II alleles, DQB1*0301, DRB1*04 and DRB1*11. CONCLUSIONS: Our results confirmed that BP180 is a major autoantigen targeted by the sera of patients with MMP. The disease-prevalent HLA class II alleles and humoral autoimmune response against the particular subsets of antigenic epitope(s) within BP180 ectodomain may contribute to the clinicopathological significance and disease severity of MMP.


Autoantigens/immunology , Genes, MHC Class II , Pemphigoid, Benign Mucous Membrane/immunology , Adult , Aged , Aged, 80 and over , Alleles , Autoantibodies/blood , Autoantigens/analysis , Basement Membrane/immunology , Carrier Proteins , Cytoskeletal Proteins , Dystonin , Female , Humans , Immunoblotting , Immunoglobulin A/blood , Immunoglobulin G/blood , Laminin/immunology , Male , Microscopy, Fluorescence , Middle Aged , Nerve Tissue Proteins , Non-Fibrillar Collagens , Pemphigoid, Benign Mucous Membrane/genetics , Phenotype , Severity of Illness Index , Skin/immunology , Collagen Type XVII
14.
Arch Virol ; 151(4): 697-707, 2006 Apr.
Article En | MEDLINE | ID: mdl-16307176

Isolate W8 of the white root rot fungus, Rosellinia necatrix, harbors three dsRNA segments, L1-, L2- and M-dsRNAs, and showed an irregular colony margin, slow growth, and moderate virulence. The M-dsRNA was previously shown to be the genome of a partitivirus, RnPV1-W8. Here a transfection protocol was developed for RnPV1-W8. Protoplasts of two virus-free isolates of R. necatrix were inoculated with purified viral particles using a polyethylene glycol-mediated method. Virus infection was confirmed by electrophoresis and Northern analysis. RnPV1-W8 introduced into the new host isolates was transmissible via hyphal anastomosis. However, the infection had no effect on the morphology and virulence of infected isolates of R. necatrix. This is the first report on the transfection of a partitivirus for R. necatrix.


Ascomycota , Pyrus/microbiology , RNA Viruses/genetics , Ascomycota/genetics , Ascomycota/pathogenicity , Ascomycota/virology , Hyphae/metabolism , Hyphae/virology , Plant Development , Plant Diseases/microbiology , Plant Roots/microbiology , Plants/microbiology , Protoplasts/virology , RNA Viruses/physiology , Transfection , Virus Replication
15.
Phys Rev E Stat Nonlin Soft Matter Phys ; 72(5 Pt 2): 056218, 2005 Nov.
Article En | MEDLINE | ID: mdl-16383738

We analyze a pair of excitable FitzHugh-Nagumo elements, each of which is coupled repulsively. While the rest state for each element is globally stable for a phase-attractive coupling, various firing patterns, including cyclic and chaotic firing patterns, exist in an phase-repulsive coupling region. Although the rest state becomes linearly unstable via a Hopf bifurcation, periodic solutions associated to the firing patterns is not connected to the Hopf bifurcation. This means that the solution branch emanating from the Hopf bifurcation is subcritical and unstable for any coupling strength. Various types of cyclic firing patterns emerge suddenly through saddle-node bifurcations. The parameter region in which different periodic solutions coexist is also found.

16.
Clin Exp Dermatol ; 30(6): 682-7, 2005 Nov.
Article En | MEDLINE | ID: mdl-16197389

Collagen XVII, or BP180, is a collagenous transmembrane protein and a structural component of the dermoepidermal anchoring complex. Molecular studies reveal that it has a globular cytosolic amino-terminal domain and flexible-rod extracellular carboxyterminal domain. The extracellular portion of collagen XVII is constitutively shed from the cell surface by ADAMs (proteinases that contain adhesive and metalloprotease domains). Cell biological analyses suggest that collagen XVII functions as a cell-matrix adhesion molecule through stabilization of the hemidesmosome complex. This concept is supported by investigations into human diseases of the dermoepidermal junction, in which collagen XVII is either genetically defective or absent (as in some forms of nonlethal junctional epidermolysis bullosa). Autoantibodies against collagen XVII (BP180) are seen in bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, linear IgA disease, lichen planus pemphigoides and pemphigoid nodularis. In vivo and in vitro studies provide evidence for a pathogenic role of these autoantibodies, and suggest that the serum level and epitope specificity of these antibodies influences disease severity and phenotype. This review summarizes the structural and biological features of collagen XVII and its role in diseases of the basement membrane zone.


Autoantigens/metabolism , Collagen Diseases/immunology , Non-Fibrillar Collagens/chemistry , Pemphigoid, Bullous/metabolism , Autoantigens/chemistry , Autoantigens/genetics , Autoantigens/immunology , Humans , Non-Fibrillar Collagens/genetics , Non-Fibrillar Collagens/immunology , Skin/immunology , Skin/metabolism , Collagen Type XVII
17.
Phys Rev Lett ; 94(13): 135002, 2005 Apr 08.
Article En | MEDLINE | ID: mdl-15904000

A low power polychromatic beam of microwaves is used to diagnose the behavior of turbulent fluctuations in the core of the JT-60U tokamak during the evolution of the internal transport barrier. A continuous reduction in the size of turbulent structures is observed concomitant with the reduction of the density scale length during the evolution of the internal transport barrier. The density correlation length decreases to the order of the ion gyroradius, in contrast with the much longer scale lengths observed earlier in the discharge, while the density fluctuation level remain similar to the level before transport barrier formation.

18.
Toxicol In Vitro ; 19(2): 191-8, 2005 Mar.
Article En | MEDLINE | ID: mdl-15649632

There is a concern on the part of public health community that adverse health consequence by thimerosal, a preservative in vaccines for infants, may occur among infants during immunization schedule. Therefore, the cytotoxic action of thimerosal was examined on lymphocytes dissociated from thymic glands of young rats using a flow cytometer and respective fluorescent probes for monitoring changes in intracellular Ca2+ concentration ([Ca2+]i) and membrane potential, and for discriminating intact living cells, apoptotic living cells and dead cells. Incubation with thimerosal at 3 microM or more (up to 30 microM) for 60 min depolarized the membranes, associated with increasing the [Ca2+]i. Thimerosal at 30 microM induced an apoptotic change in membranes of almost all living cells. Furthermore, the prolonged incubation with 30 microM thimerosal induced a loss of membrane integrity, leading to cell death. Since the blood concentration of thimerosal after receiving vaccines is theoretically submicromolar, it may be unlikely that thimerosal affects lymphocytes of infants.


Flow Cytometry/methods , Lymphocytes/drug effects , Preservatives, Pharmaceutical/toxicity , Thimerosal/toxicity , Vaccines/adverse effects , Animals , Apoptosis/drug effects , Calcium/metabolism , Cell Separation , Cell Survival/drug effects , Dose-Response Relationship, Drug , Intracellular Membranes/drug effects , Lymphocytes/metabolism , Lymphocytes/pathology , Rats , Rats, Wistar , Thymus Gland/cytology
20.
Br J Dermatol ; 151(1): 126-31, 2004 Jul.
Article En | MEDLINE | ID: mdl-15270881

BACKGROUND: Bullous pemphigoid (BP) is the most common subepidermal immunobullous disease, characterized by circulating IgG autoantibodies targeting BP180 and BP230 hemidesmosomal proteins. Several immunological studies have demonstrated that the membrane proximal noncollagenous domain NC16a of BP180 is the immunodominant region targeted by BP autoantibodies. Recently, a commercial BP180 NC16a-specific enzyme-linked immunosorbent assay (ELISA) has become available for detecting pathogenic anti-BP180 autoantibodies in BP sera. However, it remains unclear whether the diagnostic potential of the ELISA is equivalent to that of the 'gold-standard' diagnostic technique of immunofluorescence (IF). OBJECTIVES: To examine the usefulness of a commercially available BP180-NC16a ELISA in the initial serodiagnosis of BP. METHODS: Sera from a large cohort of patients with BP (n = 102) and control subjects (age- and sex-matched normal volunteers, n = 60; pemphigus foliaceus, n = 18; pemphigus vulgaris, n = 16) were assayed by BP180-NC16a ELISA. All BP sera were obtained at presentation before initiation of systemic immunosuppressive therapy. The values of IgG antibody levels measured by ELISA were compared with those measured by indirect IF on salt-split skin. Results Receiver operating characteristic analysis was used to calculate the cut-off value for the ELISA in the diagnosis of BP which maximizes both sensitivity and specificity, and to estimate the diagnostic accuracy of the ELISA as represented by the area under the curve (AUC = 0.965). A cut-off value of 9 was associated with a sensitivity of 89% (91 of 102 BP sera showed a positive result) and a specificity of 98%. Fifty-eight of 60 normal controls and all the pemphigus sera showed a negative result. There was a correlation between the mean ELISA values and indirect IF titres (Spearman rank correlation 0.286; P = 0.004). CONCLUSIONS: Our results suggest that the BP180-NC16a ELISA is a useful tool for the detection of pathogenic anti-BP180 IgG autoantibodies at the initial disease stage of BP. Because it is not only highly sensitive and specific, but is also easy to perform, is objective, and semiquantitative, the ELISA may provide valuable information for the accurate and reliable serodiagnosis of BP.


Autoantigens/analysis , Pemphigoid, Bullous/diagnosis , Aged , Aged, 80 and over , Case-Control Studies , Collagen Type VII , Enzyme-Linked Immunosorbent Assay/methods , Female , Fluorescent Antibody Technique, Indirect , Humans , Male , Middle Aged , Non-Fibrillar Collagens , Pemphigoid, Bullous/immunology , Sensitivity and Specificity , Collagen Type XVII
...